<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric C Eichenwald, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ann R Stark, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory Redding, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard Martin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchopulmonary dysplasia (BPD; also known as neonatal chronic lung disease [CLD]) is a major cause of respiratory illness in preterm infants. It is an important contributing factor in the increased risk of mortality and morbidity in the preterm population.
        </p>
        <p>
         The definition, pathogenesis, clinical features, and diagnosis of BPD are reviewed here. Other related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4992.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Prevention"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5023.html" rel="external">
          "Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6379.html" rel="external">
          "Complications and long-term pulmonary outcomes of bronchopulmonary dysplasia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/115896.html" rel="external">
          "Pulmonary hypertension associated with bronchopulmonary dysplasia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terms related to prematurity
         </strong>
         – Different degrees of prematurity are defined by gestational age (GA), which is calculated from the first day of the mother's last period, or birth weight (BW), as summarized in the table  (
         <a class="graphic graphic_table graphicRef119362" href="/z/d/graphic/119362.html" rel="external">
          table 1
         </a>
         ) and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4966.html" rel="external">
          "Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality", section on 'Definitions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terms related to neonatal lung disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          BPD
         </strong>
         – BPD is a chronic lung disease characterized by disruption of pulmonary development and/or lung injury in the context of preterm birth. As such, it applies only to preterm infants. Clinically, BPD is defined as an ongoing need for supplemental oxygen and/or respiratory support at either 28 days postnatal age or 36 weeks postmenstrual age (PMA) in a preterm neonate with radiographic evidence of parenchymal lung disease  (
         <a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">
          image 1
         </a>
         ). Various criteria are used to define the severity of BPD, as summarized in the  (
         <a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">
          table 2
         </a>
         ) and discussed below. (See
         <a class="local">
          'Definitions and severity of BPD'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chronic lung disease (CLD)
         </strong>
         – CLD is a broader term that overlaps with BPD. However, the term CLD is not restricted to preterm infants and is commonly used to describe lung disease in full-term infants who require respiratory support in the setting of various chronic pulmonary disorders (eg, pulmonary hypoplasia, congenital diaphragmatic hernia). (See
         <a class="medical medical_review" href="/z/d/html/4963.html" rel="external">
          "Congenital diaphragmatic hernia in the neonate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          DEFINITIONS AND SEVERITY OF BPD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically, BPD is defined as an ongoing need for supplemental oxygen and/or respiratory support at either 28 days postnatal age or 36 weeks postmenstrual age (PMA) in a preterm neonate (&lt;32 weeks gestations age [GA]) with radiographic evidence of parenchymal lung disease  (
         <a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
         Several definitions have been used since the first description of BPD by Northway in 1967. The severity classification schema in the 2019 definition (sometimes called the Jensen definition)  (
         <a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">
          table 2
         </a>
         ) is based primarily on the mode of respiratory support rather than the required fraction of inspired oxygen (FiO2). This definition appears to be the most accurate for predicting long-term outcomes [
         <a href="#rid1">
          1
         </a>
         ]. However, many studies define BPD based solely upon whether the infant requires supplemental oxygen or other respiratory support either at 28 postnatal days or 36 weeks PMA [
         <a href="#rid2">
          2-4
         </a>
         ]. This definition does not account for the severity of respiratory disease but it is commonly used in clinical trials because of its simplicity [
         <a href="#rid4">
          4-8
         </a>
         ]. This simple definition is also frequently used in clinical practice. (See
         <a class="local">
          'Clinical diagnosis'
         </a>
         below.)
        </p>
        <p>
         BPD definitions that have been used in clinical practice and research studies include  (
         <a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Simple clinical definition without severity classification
         </strong>
         – The simplest definition of BPD is based solely upon whether the infant requires oxygen therapy and/or respiratory support either at 28 postnatal days or 36 weeks PMA. Because of its simplicity, this definition is commonly used as an outcome measure in clinical trials [
         <a href="#rid2">
          2,3,7
         </a>
         ]. However, it does not account for the severity of respiratory disease and it is therefore less reliable as a predictor of long-term pulmonary morbidity [
         <a href="#rid4">
          4,6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions that include severity classification
         </strong>
         – Various classification schemas have been used to characterize the severity of BPD. Most of these definitions require that the infant is preterm (GA &lt;32 weeks), requires supplemental oxygen and/or respiratory support at 36 weeks PMA, and has radiographic evidence of parenchymal lung disease  (
         <a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          2019 definition (Jensen definition)
         </strong>
         — Severity categories in the 2019 definition are based primarily on the mode of respiratory support administered at 36 weeks PMA, regardless of whether the infant requires supplemental oxygen [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Mild BPD (grade I) – Requiring low-flow nasal cannula (&lt;2 L/min) at 36 weeks PMA
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Moderate BPD (grade II) – Requiring high-flow nasal cannula flow (≥2 L/min), CPAP, or noninvasive intermittent positive pressure ventilation (NIPPV) at 36 weeks PMA
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe BPD (grade III) – Requiring invasive mechanical ventilation at 36 weeks PMA
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         These definitions come from a prospective study of 2677 very preterm (VPT) and extremely preterm (EPT) infants (90 percent of the cohort had GA &lt;27 weeks) born between 2011 and 2015 [
         <a href="#rid1">
          1
         </a>
         ]. The study evaluated 18 different BPD definitions and found that the mode of respiratory support at 36 weeks PMA most accurately predicted death or serious respiratory morbidity through 18 to 26 months of corrected age.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A subsequent retrospective cohort study from the Vermont Oxford Network applied the 2019 definition to a cohort of preterm infants (gestational age from 22 to 29 weeks) born in 2018 at 715 centers in the United States [
         <a href="#rid9">
          9
         </a>
         ]. Among the 24,896 infants included in the study, 37 percent met criteria for mild or moderate BPD and 4 percent met criteria for severe BPD. Approximately 10 percent died before reaching 36 weeks PMA. Patients with severe BPD were more likely to have major comorbidities, die during birth hospitalization, or require supplemental oxygen support at discharge compared with infants with mild or moderate BPD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Earlier definitions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          2001 NICHD definition
         </strong>
         – In 2001, a consensus workshop of the National Institute of Child Health and Human Development (NICHD) developed a definitions for mild, moderate, and severe BPD that incorporated GA, oxygen and respiratory support requirement, and persistence of disease [
         <a href="#rid10">
          10,11
         </a>
         ]. However, these definitions are limited by their inability to identify infants using respiratory interventions developed after the convening of the workshop and the inability to accurately predict long-term pulmonary morbidity.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          2018 definition (revised NICHD definition)
         </strong>
         – Since the 2001 definition did not account for interventions developed after 2001 (ie, respiratory support modes that provide positive pressure without supplemental oxygen) and it did not reliably predict long-term respiratory outcomes [
         <a href="#rid12">
          12
         </a>
         ], an NICHD workshop was held in 2016 to revise the definition and identify research opportunities to address knowledge gaps [
         <a href="#rid13">
          13
         </a>
         ]. Suggested refinements to the definition included adding newer modes of noninvasive ventilation (eg, high-flow nasal cannula); reclassifying the severity categories, including a new category (grade IIIA) for early lethal BPD (ie, infants who die with lung disease between 14 days and 36 weeks postnatally); and adding the criterion for radiographic evidence of pulmonary parenchymal disease. This workshop yielded the revised 2018 NICHD definition, which is summarized in the table  (
         <a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         When evaluating the literature, it is important to keep in mind that these definitions have changed over time and thus the definition used in one study may differ from that in another [
         <a href="#rid5">
          5,14
         </a>
         ]. Many neonatal clinical trials have used BPD as a key outcome measure for evaluating a wide range of interventions. Despite the frequent reliance on this outcome in the design of clinical trials, it has been challenging to reach a lasting consensus definition as there have been changes in the population at risk (ie, greater number of surviving extremely preterm neonates) and advances in neonatal management (ie, increasing use of noninvasive ventilation modes such as continuous positive airway pressure [CPAP]). These factors have altered the pathology and clinical course of BPD and led to revisions in its definition.
        </p>
        <p>
         The challenges of applying different definitions of BPD have been described in observational studies [
         <a href="#rid5">
          5,15,16
         </a>
         ]. In a multicenter study including 765 preterm infants (GA 23 to &lt;29
         <sup>
         </sup>
         weeks), BPD was diagnosed in 30 to 60 percent of the cohort, depending on the definition used (of note, this study was conducted prior to the 2018 and 2019 revised definitions) [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         59 percent met the definition based upon supplemental oxygen requirement alone
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         41 percent met the 2001 NICHD criteria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         32 percent were diagnosed based upon physiologic testing (see
         <a class="local">
          'Physiologic testing'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Physiologic testing was the most difficult to apply, resulting in the largest number of unclassified patients. The number of unclassified patients was lowest (2 percent) using the 2001 NICHD criteria.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rates of BPD vary between institutions, likely reflecting differences in neonatal risk factors, care practices (eg, use of noninvasive ventilation, oxygen targets), and differences in the clinical criteria used to define BPD [
         <a href="#rid5">
          5,17-20
         </a>
         ]. The risk of BPD increases with decreasing gestational age (GA For extremely preterm (EPT) infants (GA &lt;28 weeks), the incidence of BPD is approximately 40 percent [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         In a multicenter study from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network of 9575 EPT infants born between 2003 and 2007, the overall incidence of BPD (defined as requiring supplemental oxygen at 36 weeks postmenstrual age) according to GA was as follows [
         <a href="#rid21">
          21
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         22 weeks – 85 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         23 weeks – 73 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         24 weeks – 69 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         25 weeks – 55 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         26 weeks – 44 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         27 weeks – 34 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         28 weeks – 23 percent
        </p>
        <p>
        </p>
        <p>
         The severity of BPD also increases with decreasing GA. In a study from the Vermont Oxford Network of 24,896 infants &lt;30 weeks GA, the risk of severe BPD (ie, grade III using the 2019 criteria  (
         <a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">
          table 2
         </a>
         )) increased tenfold from 0.8 percent for infants born at 29 weeks GA to 10 percent for those born at 22 weeks GA [
         <a href="#rid9">
          9
         </a>
         ]. Grade III BPD was associated with increased risk of death and other serious comorbidities.
        </p>
        <p>
         It is unclear whether the incidence of BPD is changing.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a report from the NICHD Neonatal Research Network, the incidence of BPD had not changed over a 20-year period from 1993 and 2012 except for an increased rate among infants born at 26 to 27 weeks gestation between 2009 and 2012 [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study using a United States national database (Nationwide Inpatient Sample) reported a decrease in the rate of BPD of 4.3 percent per year for the study period between 1993 and 2006 [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, a study in Japan of 19,370 EPT infants reported an increase in the incidence of BPD for the 17,126 survivors between 2003 and 2016 (46 versus 52 percent) [
         <a href="#rid24">
          24
         </a>
         ]. During the same period of time, there was an increase in survival rate (81 to 92 percent).
        </p>
        <p>
        </p>
        <p>
         One study from the United States reported that Black infants had a lower risk of BPD compared with White infants even after adjusting for confounding risk factors (GA, antenatal steroid use, and intubation and surfactant administration at birth) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Rates of BPD tend to be higher at hospitals at high altitude since infants managed at high altitude more often require supplemental oxygen therapy. However, the differences are less dramatic if adjustments are made to account for the barometric pressure [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1183625918">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The etiology of BPD is multifactorial and involves disruption of lung development and injury due to antenatal (intrauterine growth restriction, maternal smoking) and/or postnatal factors (eg, mechanical ventilation, oxygen toxicity, infection) that cause inflammation and damage to the highly vulnerable premature lung [
         <a href="#rid28">
          28
         </a>
         ]. Numerous risk factors have been identified. Risk prediction models have been developed, but many are based upon single-center data from earlier eras and few have been externally validated in contemporary populations [
         <a href="#rid29">
          29-31
         </a>
         ].
        </p>
        <p>
         The following section discusses important risk factors that contribute to the development of BPD.
        </p>
        <p class="headingAnchor" id="H2266100999">
         <span class="h2">
          Prematurity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The premature lung is susceptible to damage because of its immature, underdeveloped airway-supporting structures, surfactant deficiency, decreased compliance, underdeveloped antioxidant mechanisms, and inadequate fluid clearance [
         <a href="#rid32">
          32-34
         </a>
         ]. The premature lung's structural and functional immaturity increases the risk of injury and disruption of normal pulmonary microvascular and alveolar development from external antenatal and postnatal insults. As discussed above, the incidence of BPD increases with decreasing GA; the risk is greatest among extremely preterm (EPT) infants (gestational age [GA] &lt;28 weeks). (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H711544384">
         <span class="h2">
          Fetal growth restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal (intrauterine) growth restriction in preterm infants is an independent risk factor for BPD [
         <a href="#rid35">
          35-37
         </a>
         ]. Growth restriction may have a significant impact on the vulnerability of lung injury and vasculogenesis. In a case-control study of 2255 infants with &lt;33 weeks GA, infants born small for GA had more than twice the risk of BPD (odds ratio [OR] 2.73, 95% CI 2.11-3.55) [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">
          "Infants with fetal (intrauterine) growth restriction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2038315092">
         <span class="h2">
          Maternal smoking
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maternal smoking negatively affects lung development in offspring and contributes to the risk of BPD [
         <a href="#rid13">
          13,39,40
         </a>
         ]. In a prospective, longitudinal study of 587 preterm infants (GA &lt;34 weeks and birth weight [BW] between 500 and 1250 g), maternal smoking was independently associated with risk of BPD (OR 2.02, 95% CI 1.09-3.74) [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">
          "Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate", section on 'Postnatal'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2256625909">
         <span class="h2">
          Mechanical ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ventilator-induced lung injury in infants with BPD is primarily due to large tidal volumes (volutrauma) that overdistend airways and airspaces [
         <a href="#rid41">
          41-43
         </a>
         ]. Barotrauma (exposure to high airway pressures) plays less of a role. For EPT infants who received mechanical ventilation at postnatal day 7, the risk of BPD is high [
         <a href="#rid44">
          44
         </a>
         ]. More aggressive ventilation (eg, large tidal volumes and/or low partial pressure of carbon dioxide [PaCO
         <sub>
          2
         </sub>
         ] levels) is associated with increased risk of BPD [
         <a href="#rid2">
          2,45
         </a>
         ].
        </p>
        <p>
         Because aggressive mechanical ventilation plays a major role in the pathogenesis of BPD, management of preterm infants requiring respiratory support has shifted towards initial use of noninvasive modalities (eg, nasal continuous airway pressure [nCPAP]) to avoid mechanical ventilation, if possible. Between-center differences in the approach for respiratory support (including differences in criteria for intubation) may explain some of the variation among hospitals in BPD rates. (See
         <a class="medical medical_review" href="/z/d/html/4992.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Prevention", section on 'Ventilation strategies to minimize lung injury'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Respiratory support devices'
         </a>
         .)
        </p>
        <p>
         Despite the use of noninvasive respiratory support, up to 50 percent of EPT infants require intubation and mechanical ventilation. If mechanical ventilation is needed, a more conservative approach of volume-targeted ventilation using small tidal volumes is utilized [
         <a href="#rid46">
          46
         </a>
         ]. The approach is summarized in the table  (
         <a class="graphic graphic_table graphicRef131155" href="/z/d/graphic/131155.html" rel="external">
          table 3
         </a>
         ) and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1102378384">
         <span class="h2">
          Oxygen toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         High concentrations of inspired oxygen can damage the lungs, although the exact level or duration of exposure that is unsafe is not known. The risk of BPD for EPT infants rises with increasing accumulation of supplemental oxygen during the first two weeks after delivery [
         <a href="#rid47">
          47
         </a>
         ]. It is thought that cellular damage is caused by the overproduction of cytotoxic reactive oxygen metabolites (ie, superoxide free radical, hydrogen peroxide, hydroxyl free radical, and singlet oxygen), which overwhelm the neonate's immature antioxidant system, resulting in inflammation and lung injury [
         <a href="#rid48">
          48
         </a>
         ]. Preterm infants are most susceptible to oxygen toxicity compared with term infants due to their more immature antioxidant enzyme systems (superoxide dismutase, catalase, glutathione peroxidase, glutathione-S-transferase) [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
         Because of the adverse effects of high oxygen concentration, supplemental oxygen therapy in preterm neonates should aim to meet the metabolic needs of the infant while avoiding hyperoxia and high oxygen concentrations. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/112392.html" rel="external">
          "Neonatal target oxygen levels for preterm infants", section on 'Oxygen target levels'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3862453886">
         <span class="h2">
          Infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both antenatal and postnatal infections are associated with increased risk of BPD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antenatal infections
         </strong>
         – Studies have reached variable conclusions regarding the association between BPD and maternal intraamniotic infection (IAI; also called chorioamnionitis) [
         <a href="#rid51">
          51-54
         </a>
         ]. A systematic review identified 158 studies examining this association; however, the definitions of IAI and BPD varied considerably between studies [
         <a href="#rid54">
          54
         </a>
         ]. The association between maternal IAI and BPD was strongest in studies that defined IAI based on histology and defined BPD as oxygen requirement at 28 postnatal days (pooled OR 2.58, 95% CI 1.99-3.34; based on 43 studies). The association was least pronounced in studies that defined IAI clinically and defined BPD as oxygen requirement at 36 weeks PMA (pooled OR 1.24, 95% CI 1.03-1.49; based on 31 studies).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since IAI is known to substantially increase the risks of preterm birth and neonatal sepsis, it remains unclear whether IAI is an independent risk factor for BPD. It is possible that the association with BPD is indirect and largely due to the impact of prematurity and postnatal infection. However, it is hypothesized that IAI plays a direct role due to inflammatory changes that may contribute to development of BPD. This is supported by studies that have demonstrated increased concentrations of proinflammatory cytokines (interleukin [IL]-6, IL-1 beta, and IL-8) in the amniotic fluid of infants who subsequently develop BPD compared with those who did not [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="local">
          'Pathogenesis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postnatal infections
         </strong>
         – The risk of BPD is increased in infants who develop postnatal bacterial or fungal infections. This was illustrated in an observational study from a single tertiary center of 798 preterm infants (mean GA 27.4 weeks) born between 1992 and 2004 that reported neonatal sepsis was associated with a nearly three-fold increased risk of BPD (OR 2.71, 95% CI 1.64-4.51) [
         <a href="#rid56">
          56
         </a>
         ]. Infants with candidemia had the highest risk of developing BPD (OR 8.68, 95% CI 1.65-45.63).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Infection with
         <em>
          Ureaplasma urealyticum
         </em>
         has been reported to cause a sustained dysregulated inflammatory response that impairs lung development, resulting in BPD [
         <a href="#rid57">
          57,58
         </a>
         ]. A systematic review of the literature noted that infants with pulmonary colonization with
         <em>
          Ureaplasma
         </em>
         were more likely to develop BPD than those without colonization at 36 weeks postmenstrual age (OR 2.22, 95% CI 1.42-3.47) or at 28 days of life (OR 3.04, 95% CI 2.41-3.83) [
         <a href="#rid59">
          59
         </a>
         ]. Whether eradication of
         <em>
          Ureaplasma
         </em>
         respiratory colonization acquired in utero by preterm infants reduces the incidence of BPD requires testing in clinical trials [
         <a href="#rid60">
          60,61
         </a>
         ] In a randomized trial of
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         to improve Ureaplasma free-survival in 121 preterm infants (GA &lt;29 weeks), subgroup analysis found that physiological BPD-free survival was 50 percent (95% CI 19 - 81 percent) among azithromycin-assigned infants with lower respiratory tract Ureaplasma colonization versus 18 percent (95% CI 2 - 52 percent) in placebo-treated infants [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H944423831">
         <span class="h2">
          Patent ductus arteriosus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of the patent ductus arteriosus (PDA) in the development of BPD is uncertain. Although clinical trials conducted before 2000 consistently reported that PDA was associated with BPD, the accuracy of these results has been questioned due to study design issues [
         <a href="#rid13">
          13
         </a>
         ]. Subsequent studies of prophylactic
         <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">
          indomethacin
         </a>
         to prevent PDA resulted in conflicting results on the risk of BPD [
         <a href="#rid63">
          63,64
         </a>
         ]. Ongoing research efforts are focused on comparing early versus no or late treatment of PDA and hope to address whether a persistent PDA contributes to the development of BPD. (See
         <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">
          "Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Consequences of a PDA'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H852233764">
         <span class="h2">
          Genetic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         It remains uncertain whether there is a genetic predisposition that may influence the development of BPD as illustrated in the difference in results between twin cohort studies of preterm infants [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p>
         Similarly, conflicting results were reported in studies trying to identify genetic factors associated with BPD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A genome-wide association study (GWAS) that included 899 cases of BPD and 827 controls did not identify any single-nucleotide polymorphisms (SNPs) associated with BPD [
         <a href="#rid67">
          67
         </a>
         ]. These negative findings may have missed a genetic risk due to epigenetic effects, copy number variations, or joint effects of multiple SNPs or interaction among them.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of 157 preterm infants who developed respiratory distress syndrome requiring mechanical ventilation, two specific SNPs of a gene encoding for endothelial nitric oxide synthase (eNOS) were independent predictors of an increased risk of developing BPD [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study of 751 infants of whom 428 developed BPD or died, pathway analysis of a GWAS identified involvement of several known pathways of lung development and repair that were significant for severe BPD or death and indicated specific molecules that were increased in patients with BPD [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Further studies are required to determine whether or not there is a genetic predisposition, and if so, what the underlying genetic factors are.
        </p>
        <p class="headingAnchor" id="H3336012353">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H91209896">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The characteristic pathologic finding of BPD is disruption of the late canalicular or saccular phases of lung development [
         <a href="#rid10">
          10,32,70
         </a>
         ]. The following pathologic findings occur:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased septation and alveolar hypoplasia lead to fewer and larger alveoli with a reduction in the surface area available for gas exchange.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysregulation of pulmonary vasculature development with abnormal distribution of alveolar capillaries and thickening of the muscle layer of the pulmonary arterioles, which results in an increase in pulmonary resistance. Early disruption of vasculogenesis leading to pulmonary vascular disease results in pulmonary hypertension and contributes to morbidity and mortality [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased elastic tissue formation and thickening of the interstitium. These tissue deformations may, in turn, compromise septation and capillary development. In one autopsy study, the amount of elastic tissue, septal thickness, and alveolar and duct diameters increased with the severity of BPD [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In older studies (before the 1980s), which generally included more mature infants (GA ≥28 weeks) cared for prior to the availability of surfactant replacement therapy and before widespread use of antenatal steroids, the prominent pathologic findings were airway injury, inflammation, and parenchymal fibrosis due to mechanical ventilation and oxygen toxicity [
         <a href="#rid10">
          10,70
         </a>
         ]. Similar changes may rarely be seen in the contemporary era in surfactant-treated infants who develop severe BPD. In these severely affected infants, fibrosis, bronchial smooth muscle hypertrophy, and interstitial edema may be superimposed on the characteristic reduced numbers of alveoli and capillaries. Pulmonary vascular changes, such as abnormal arterial muscularization and obliteration of vessels, may also occur.
        </p>
        <p class="headingAnchor" id="H2740505279">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of BPD is multifactorial. It results from lung injury and disruption of lung development due to antenatal and/or postnatal factors that cause inflammation and damage to the highly vulnerable premature lung [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammation
         </strong>
         – The development of BPD may begin before birth in some newborns through intrauterine exposure to proinflammatory cytokines, possibly due to chorioamnionitis. However, this relationship remains controversial. Inflammation is a common pathway for many injuries that may disrupt late lung development. Evidence for a role for lung inflammation in the pathogenesis is based on the elevated concentration of proinflammatory and chemotactic factors in the tracheal aspirates of infants who subsequently develop BPD compared with those without BPD [
         <a href="#rid48">
          48,73-75
         </a>
         ]. The presence of these mediators is associated with complement activation, increased vascular permeability, protein leakage, and mobilization of neutrophils into the interstitial and alveolar compartments. Release of reactive oxygen radicals, elastase, and collagenase by activated neutrophils results in lung damage [
         <a href="#rid76">
          76
         </a>
         ]. Interaction between macrophages and other cell types (eg, endothelial and epithelial cells) perpetuates the production of proinflammatory mediators and sustains the cycle of lung injury. Persistence of factors (eg, macrophage inflammatory protein-1 and IL-8) and decreases of counterregulatory cytokines (eg, IL-10, IL-17) may lead to unregulated and persistent inflammation [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Late surfactant deficiency
         </strong>
         – Delayed recovery or late deficiency of postnatal surfactant may play a role in the pathogenesis of BPD. In a study of 68 ventilator-dependent preterm infants (GA between 23 and 30 weeks), 75 percent of tracheal aspirates exhibited abnormally low surface tension [
         <a href="#rid77">
          77
         </a>
         ]. In these samples, surfactant proteins A, B, and C were reduced by 50, 80, and 72 percent, respectively. There also appears to be a temporal association between samples with low surface tension and episodes of infection and respiratory deterioration. These results suggest that preterm infants who require continued respiratory support have transient surfactant dysfunction or deficiency, which may affect their clinical status. However, it appears that late administration of surfactant does not appear to reduce the risk of BPD, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4997.html" rel="external">
          "Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Timing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impaired angiogenesis
         </strong>
         — There is increasing evidence suggesting that growth of pulmonary blood vessels actively promotes alveolar growth. Disruption of angiogenesis has been proposed as a mechanism that impairs alveolarization, thereby contributing to the new form of BPD [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Support for the potential role of impaired angiogenesis in the pathogenesis of BPD includes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one study, elevated cord plasma levels of endostatin, an antiangiogenic growth factor, was associated with an increased risk of BPD in very low birth weight (VLBW) infants (BW &lt;1500 g) [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study of preterm infants less than 35 weeks gestation, cord blood level of placenta growth factor (PlGF), but not vascular endothelial growth factor or soluble fms-like tyrosine kinase-1, was elevated in infants who subsequently developed BPD [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Observational studies have shown that the risk of BPD is twofold greater in infants born to mothers with preeclampsia compared with those born to mothers without preeclampsia [
         <a href="#rid81">
          81,82
         </a>
         ]. These findings suggest factors that trigger maternal endothelial dysfunction (impaired angiogenesis), resulting in preeclampsia, are transferred to infants, which may contribute to the pathogenesis of BPD. (See
         <a class="medical medical_review" href="/z/d/html/6760.html" rel="external">
          "Preeclampsia: Pathogenesis", section on 'Role of systemic endothelial dysfunction in clinical findings'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1116491853">
         <span class="h2">
          Physiology
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal pulmonary function
         </strong>
         — Patients with severe BPD typically have both hypoxemia and hypercapnia and often require positive pressure ventilatory support (either with noninvasive ventilation or invasive mechanical ventilation). Abnormalities in pulmonary function include decreased tidal volume and poor lung compliance (ie, restrictive lung physiology). However, the lung disease can be either restrictive or obstructive and some patients may have a mixed picture [
         <a href="#rid83">
          83
         </a>
         ]. Lung compliance is dynamic and there may be intermittent airway obstruction resulting in gas trapping and hyperinflation with abnormal distribution of overventilated and underventilated areas of the lung [
         <a href="#rid84">
          84
         </a>
         ]. Infants with BPD-associated tracheobronchomalacia can have obstruction due to airway collapse during expiration. (See
         <a class="medical medical_review" href="/z/d/html/6379.html" rel="external">
          "Complications and long-term pulmonary outcomes of bronchopulmonary dysplasia", section on 'Acquired tracheobronchomalacia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic effects
         </strong>
         – Severely affected patients may develop pulmonary hypertension. Pulmonary vascular resistance is increased in these patients because of disruption of pulmonary vascular growth and/or reduced cross-sectional area of pulmonary vessels. Alveolar hypoxia in underventilated areas of the lung induces local vasoconstriction. The high microvascular pressure promotes increased fluid filtration into the perivascular interstitium. Elevated right atrial pressure inhibits pulmonary lymphatic drainage, further promoting pulmonary edema. (See
         <a class="medical medical_review" href="/z/d/html/115896.html" rel="external">
          "Pulmonary hypertension associated with bronchopulmonary dysplasia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         BPD is associated with multiple risk factors, including prematurity, mechanical ventilation, oxygen toxicity, and infection. It occurs most frequently in extremely preterm (EPT) infants (gestational age [GA] &lt;28 weeks) [
         <a href="#rid13">
          13,85
         </a>
         ]. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
         Infants who require supplemental oxygen with a fraction of inspired oxygen (FiO
         <sub>
          2
         </sub>
         ) &gt;0.25 at two weeks of age are at increased risk for developing BPD; however, early need for supplemental oxygen does not necessarily predict subsequent development of BPD [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The physical examination is variable. Infants with BPD usually are tachypneic. Depending upon the extent of pulmonary edema and/or atelectasis, they may have mild to severe retractions, and scattered rales may be audible. Intermittent expiratory wheezing may be present in infants with airway narrowing from scar formation, constriction, mucus retention, collapse, and/or edema.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Chest radiograph
         </span>
         <span class="headingEndMark">
          —
         </span>
         As BPD evolves, the chest radiograph also changes from clear lung fields to findings that include diffuse haziness and a coarse interstitial pattern, which reflect atelectasis, inflammation, and/or pulmonary edema  (
         <a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">
          image 1
         </a>
         ). Lung volumes are normal or low. With further evolution of the disease, there may be areas of atelectasis that alternate with areas of gas trapping, related to airway obstruction from secretions or bronchiolar injury.
        </p>
        <p>
         The chest radiograph in infants who develop severe BPD shows hyperinflation. Streaky densities or cystic areas may be prominent, corresponding to fibrotic changes  (
         <a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">
          image 1
         </a>
         ). During acute exacerbations, pulmonary edema may be apparent.
        </p>
        <p class="headingAnchor" id="H4045642">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3543929099">
         <span class="h2">
          Clinical diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically, BPD is defined as a need for supplemental oxygen and/or respiratory support at either 28 days postnatal age or 36 weeks postmenstrual age (PMA) in a preterm neonate with radiographic evidence of parenchymal lung disease  (
         <a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">
          image 1
         </a>
         ). The severity of BPD is classified according to the amount of respiratory support required at 36 weeks PMA, as summarized in the table  (
         <a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">
          table 2
         </a>
         ) and discussed above. (See
         <a class="local">
          'Definitions and severity of BPD'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4010998700">
         <span class="h2">
          Physiologic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         If there is uncertainty about the diagnosis, physiologic testing (oxygen reduction test) can be performed to define the true need for supplemental oxygen at 28 days postnatal age or 36 weeks PMA.
        </p>
        <p>
         Infants are classified as having BPD if the oxygen saturation falls below 90 percent within 60 minutes of being placed in room air. When performing physiologic testing at high altitudes, corrections for altitude are necessary.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          CLINICAL COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most infants improve gradually in the two to four months after the diagnosis of BPD is made. As pulmonary function improves with growth, they can be weaned to continuous positive airway pressure (CPAP) or high-flow nasal cannula (HFNC) with supplemental oxygen, then supplemental oxygen alone, until they can maintain adequate oxygenation when breathing room air. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Respiratory support devices'
         </a>
         .)
        </p>
        <p>
         Some infants develop severe BPD with prolonged ventilator dependence [
         <a href="#rid86">
          86
         </a>
         ]. These infants typically have substantial clinical instability during the first few weeks after birth with swings in oxygen saturation and intermittent episodes of acute deterioration requiring increased ventilator support [
         <a href="#rid87">
          87
         </a>
         ]. The instability typically improves slowly after four to six weeks. However, some infants require long-term ventilator support or supplemental oxygen beyond six months of age. (See
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Pharmacologic therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6379.html" rel="external">
          "Complications and long-term pulmonary outcomes of bronchopulmonary dysplasia"
         </a>
         .)
        </p>
        <p>
         Infants with severe BPD are more likely to have other comorbid neonatal conditions (sepsis, intraventricular hemorrhage, patent ductus arteriosus, necrotizing enterocolitis, retinopathy of prematurity) [
         <a href="#rid9">
          9
         </a>
         ]. In addition, they are at risk for other chronic complications, including pulmonary hypertension, acquired tracheobronchomalacia, subglottic stenosis, asthma-like symptoms, poor growth, and neurodevelopmental impairment. These complications are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6379.html" rel="external">
          "Complications and long-term pulmonary outcomes of bronchopulmonary dysplasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Morbidities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2816130037">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115866.html" rel="external">
          "Society guideline links: Bronchopulmonary dysplasia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25323989">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83626.html" rel="external">
          "Patient education: Bronchopulmonary dysplasia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance
         </strong>
         – Bronchopulmonary dysplasia (BPD) is a chronic lung disease characterized by disruption of pulmonary development and/or lung injury in the context of preterm birth. It remains a major complication of prematurity, resulting in significant mortality and morbidity. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Outcome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – The risk of BPD increases with decreasing gestational age (GA). For extremely preterm (EPT) infants (GA &lt;28 weeks), the incidence of BPD is approximately 40 percent. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         –Risk factors that contribute to the development of BPD include (see
         <a class="local">
          'Risk factors'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prematurity (see
         <a class="local">
          'Prematurity'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fetal growth restriction (see
         <a class="local">
          'Fetal growth restriction'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maternal smoking (see
         <a class="local">
          'Maternal smoking'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mechanical ventilation and oxygen toxicity (see
         <a class="local">
          'Mechanical ventilation'
         </a>
         above and
         <a class="local">
          'Oxygen toxicity'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infections (see
         <a class="local">
          'Infection'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patent ductus arteriosus (see
         <a class="local">
          'Patent ductus arteriosus'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic factors (see
         <a class="local">
          'Genetic factors'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Physical examination
         </strong>
         – Physical findings of BPD vary. Most affected infants are tachypneic. Other findings include retractions, rales, and wheezes. (See
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chest radiograph
         </strong>
         – The chest radiograph in infants with BPD changes with evolution of the disease from clear lung fields to findings that include diffuse haziness and a coarse interstitial pattern, which reflect atelectasis, inflammation, and/or pulmonary edema  (
         <a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">
          image 1
         </a>
         ). (See
         <a class="local">
          'Chest radiograph'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – A clinical diagnosis of BPD is made based upon meeting the following criteria  (
         <a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The infants is preterm (&lt;32 weeks GA), and
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is radiographic evidence of parenchymal lung disease  (
         <a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">
          image 1
         </a>
         ), and
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The infant requires supplemental oxygen and/or respiratory support at either 28 days postnatal age or 36 weeks postmenstrual age (PMA)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If there is uncertainty, the diagnosis can be confirmed by physiologic testing (oxygen reduction test), which involves placing the infant in room air to document the need for supplemental oxygen. (See
         <a class="local">
          'Physiologic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severity
         </strong>
         – We use the following classification schema to characterize the severity of BPD  (
         <a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Definitions and severity of BPD'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mild BPD (grade I) – Requiring low-flow nasal cannula (&lt;2 L/min) at 36 weeks PMA
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Moderate BPD (grade II) – Requiring high-flow nasal cannula flow (≥2 L/min), continuous positive airway pressure, or noninvasive intermittent positive pressure ventilation (NIPPV) at 36 weeks PMA
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe BPD (grade III) – Requiring invasive mechanical ventilation at 36 weeks PMA
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical course
         </strong>
         – Most infants with BPD improve gradually during the first two to four months. Those with severe disease (grade III BPD) may require prolonged mechanical ventilation and are at risk for developing pulmonary hypertension and other complications. (See
         <a class="local">
          'Clinical course'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6379.html" rel="external">
          "Complications and long-term pulmonary outcomes of bronchopulmonary dysplasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115896.html" rel="external">
          "Pulmonary hypertension associated with bronchopulmonary dysplasia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H62072130">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge James Adams, Jr., MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Jensen EA, Dysart K, Gantz MG, et al. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med 2019; 200:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraybill EN, Runyan DK, Bose CL, Khan JH. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams. J Pediatr 1989; 115:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials. Pediatrics 1990; 86:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poindexter BB, Feng R, Schmidt B, et al. Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program. Ann Am Thorac Soc 2015; 12:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall DD, Kotelchuck M, Young TE, et al. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999; 104:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beam KS, Aliaga S, Ahlfeld SK, et al. A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. J Perinatol 2014; 34:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen EA, Wright CJ. Bronchopulmonary Dysplasia: The Ongoing Search for One Definition to Rule Them All. J Pediatr 2018; 197:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen EA, Edwards EM, Greenberg LT, et al. Severity of Bronchopulmonary Dysplasia Among Very Preterm Infants in the United States. Pediatrics 2021; 148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maitre NL, Ballard RA, Ellenberg JH, et al. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. J Perinatol 2015; 35:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins RD, Jobe AH, Koso-Thomas M, et al. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. J Pediatr 2018; 197:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hines D, Modi N, Lee SK, et al. Scoping review shows wide variation in the definitions of bronchopulmonary dysplasia in preterm infants and calls for a consensus. Acta Paediatr 2017; 106:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim F, Bateman DA, Goldshtrom N, et al. Revisiting the definition of bronchopulmonary dysplasia in premature infants at a single center quaternary neonatal intensive care unit. J Perinatol 2021; 41:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Lu YK, Wu YY, et al. Comparison of two novel diagnostic criteria for bronchopulmonary dysplasia in predicting adverse outcomes of preterm infants: a retrospective cohort study. BMC Pulm Med 2023; 23:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellsbury DL, Acarregui MJ, McGuinness GA, et al. Controversy surrounding the use of home oxygen for premature infants with bronchopulmonary dysplasia. J Perinatol 2004; 24:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196:147.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Marter LJ, Allred EN, Pagano M, et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 2000; 105:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughon M, Allred EN, Bose C, et al. Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants. Pediatrics 2009; 123:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll BJ, Hansen NI, Bell EF, et al. Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA 2015; 314:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stroustrup A, Trasande L. Epidemiological characteristics and resource use in neonates with bronchopulmonary dysplasia: 1993-2006. Pediatrics 2010; 126:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakashima T, Inoue H, Sakemi Y, et al. Trends in Bronchopulmonary Dysplasia Among Extremely Preterm Infants in Japan, 2003-2016. J Pediatr 2021; 230:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan RM, Feng R, Bazacliu C, et al. Black Race Is Associated with a Lower Risk of Bronchopulmonary Dysplasia. J Pediatr 2019; 207:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Britton JR. Altitude, oxygen and the definition of bronchopulmonary dysplasia. J Perinatol 2012; 32:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández CL, Fajardo CA, Favareto MV, et al. Oxygen dependency as equivalent to bronchopulmonary dysplasia at different altitudes in newborns ⩽ 1500 g at birth from the SIBEN network. J Perinatol 2014; 34:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol 2014; 100:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onland W, Debray TP, Laughon MM, et al. Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study. BMC Pediatr 2013; 13:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romijn M, Dhiman P, Finken MJJ, et al. Prediction Models for Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta-Analysis. J Pediatr 2023; 258:113370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwok TC, Batey N, Luu KL, et al. Bronchopulmonary dysplasia prediction models: a systematic review and meta-analysis with validation. Pediatr Res 2023; 94:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357:1946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langston C, Kida K, Reed M, Thurlbeck WM. Human lung growth in late gestation and in the neonate. Am Rev Respir Dis 1984; 129:607.
          </a>
         </li>
         <li class="breakAll">
          Randell SH, Young SI. nique features of the immature lung that make it vulnerable to injury. In: Chronic Lung Disease in Early Infancy, Bland RD, Coalson JJ (Eds), Marcel Dekk, New York 2000. p.377.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bose C, Van Marter LJ, Laughon M, et al. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. Pediatrics 2009; 124:e450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torchin H, Ancel PY, Goffinet F, et al. Placental Complications and Bronchopulmonary Dysplasia: EPIPAGE-2 Cohort Study. Pediatrics 2016; 137:e20152163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeitlin J, El Ayoubi M, Jarreau PH, et al. Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort. J Pediatr 2010; 157:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson L, Haglund B, Odlind V, et al. Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia. Acta Paediatr 2015; 104:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McEvoy CT, Spindel ER. Pulmonary Effects of Maternal Smoking on the Fetus and Child: Effects on Lung Development, Respiratory Morbidities, and Life Long Lung Health. Paediatr Respir Rev 2017; 21:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrow LA, Wagner BD, Ingram DA, et al. Antenatal Determinants of Bronchopulmonary Dysplasia and Late Respiratory Disease in Preterm Infants. Am J Respir Crit Care Med 2017; 196:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez LA, Peevy KJ, Moise AA, Parker JC. Chest wall restriction limits high airway pressure-induced lung injury in young rabbits. J Appl Physiol (1985) 1989; 66:2364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlton DP, Cummings JJ, Scheerer RG, et al. Lung overexpansion increases pulmonary microvascular protein permeability in young lambs. J Appl Physiol (1985) 1990; 69:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björklund LJ, Ingimarsson J, Curstedt T, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997; 42:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughon MM, Langer JC, Bose CL, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am J Respir Crit Care Med 2011; 183:1715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garland JS, Buck RK, Allred EN, Leviton A. Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome. Arch Pediatr Adolesc Med 1995; 149:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klingenberg C, Wheeler KI, McCallion N, et al. Volume-targeted versus pressure-limited ventilation in neonates. Cochrane Database Syst Rev 2017; 10:CD003666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wai KC, Kohn MA, Ballard RA, et al. Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns. J Pediatr 2016; 177:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvira CM, Morty RE. Can We Understand the Pathobiology of Bronchopulmonary Dysplasia? J Pediatr 2017; 190:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank L, Sosenko IR. Development of lung antioxidant enzyme system in late gestation: possible implications for the prematurely born infant. J Pediatr 1987; 110:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgeson GD, Szony BJ, Streitman K, et al. Antioxidant enzyme activities are decreased in preterm infants and in neonates born via caesarean section. Eur J Obstet Gynecol Reprod Biol 2002; 103:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soraisham AS, Singhal N, McMillan DD, et al. A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. Am J Obstet Gynecol 2009; 200:372.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartling L, Liang Y, Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2012; 97:F8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacaze-Masmonteil T. That chorioamnionitis is a risk factor for bronchopulmonary dysplasia--the case against. Paediatr Respir Rev 2014; 15:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villamor-Martinez E, Álvarez-Fuente M, Ghazi AMT, et al. Association of Chorioamnionitis With Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review, Meta-analysis, and Metaregression. JAMA Netw Open 2019; 2:e1914611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon BH, Romero R, Jun JK, et al. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1997; 177:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahra MM, Beeby PJ, Jeffery HE. Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study. Pediatrics 2009; 123:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannaford K, Todd DA, Jeffery H, et al. Role of ureaplasma urealyticum in lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 1999; 81:F162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viscardi RM, Hasday JD. Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence. Pediatr Res 2009; 65:84R.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe J, Watkins WJ, Edwards MO, et al. Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. Pediatr Infect Dis J 2014; 33:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viscardi RM, Othman AA, Hassan HE, et al. Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose. Antimicrob Agents Chemother 2013; 57:2127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poets CF, Lorenz L. Prevention of bronchopulmonary dysplasia in extremely low gestational age neonates: current evidence. Arch Dis Child Fetal Neonatal Ed 2018; 103:F285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viscardi RM, Terrin ML, Magder LS, et al. Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants. Arch Dis Child Fetal Neonatal Ed 2020; 105:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liebowitz M, Clyman RI. Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes. J Pediatr 2017; 187:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen EA, Dysart KC, Gantz MG, et al. Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. J Pediatr 2017; 186:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavoie PM, Pham C, Jang KL. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics 2008; 122:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parad RB, Winston AB, Kalish LA, et al. Role of Genetic Susceptibility in the Development of Bronchopulmonary Dysplasia. J Pediatr 2018; 203:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang H, St Julien KR, Stevenson DK, et al. A genome-wide association study (GWAS) for bronchopulmonary dysplasia. Pediatrics 2013; 132:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poggi C, Giusti B, Gozzini E, et al. Genetic Contributions to the Development of Complications in Preterm Newborns. PLoS One 2015; 10:e0131741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambalavanan N, Cotten CM, Page GP, et al. Integrated genomic analyses in bronchopulmonary dysplasia. J Pediatr 2015; 166:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 1998; 29:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. Curr Opin Pediatr 2013; 25:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thibeault DW, Mabry SM, Ekekezie II, Truog WE. Lung elastic tissue maturation and perturbations during the evolution of chronic lung disease. Pediatrics 2000; 106:1452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groneck P, Götze-Speer B, Oppermann M, et al. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 1994; 93:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambalavanan N, Carlo WA, D'Angio CT, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 2009; 123:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright CJ, Kirpalani H. Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies? Pediatrics 2011; 128:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies PL, Spiller OB, Beeton ML, et al. Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Thorax 2010; 65:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrill JD, Ballard RA, Cnaan A, et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res 2004; 56:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thébaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 2007; 175:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janér J, Andersson S, Kajantie E, Lassus P. Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants. Pediatrics 2009; 123:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang WC, Chen CY, Chou HC, et al. Angiogenic Factors in Cord Blood of Preterm Infants Predicts Subsequently Developing Bronchopulmonary Dysplasia. Pediatr Neonatol 2015; 56:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen AR, Barnés CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr 2010; 156:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson L, Haglund B, Odlind V, et al. Prenatal inflammatory risk factors for development of bronchopulmonary dysplasia. Pediatr Pulmonol 2014; 49:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepherd EG, Clouse BJ, Hasenstab KA, et al. Infant Pulmonary Function Testing and Phenotypes in Severe Bronchopulmonary Dysplasia. Pediatrics 2018; 141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watts JL, Ariagno RL, Brady JP. Chronic pulmonary disease in neonates after artificial ventilation: distribution of ventilation and pulmonary interstitial emphysema. Pediatrics 1977; 60:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh MC, Szefler S, Davis J, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 2006; 117:S52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abman SH, Collaco JM, Shepherd EG, et al. Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia. J Pediatr 2017; 181:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin RJ, Di Fiore JM, Walsh MC. Hypoxic Episodes in Bronchopulmonary Dysplasia. Clin Perinatol 2015; 42:825.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4987 Version 51.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30995069" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2500509" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2235227" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3174313" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26397992" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10585987" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25010224" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29605396" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Bronchopulmonary Dysplasia: The Ongoing Search for One Definition to Rule Them All.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34078747" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Severity of Bronchopulmonary Dysplasia Among Very Preterm Infants in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11401896" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16322158" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25811285" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29551318" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Bronchopulmonary Dysplasia: Executive Summary of a Workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27862302" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Scoping review shows wide variation in the definitions of bronchopulmonary dysplasia in preterm infants and calls for a consensus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33649435" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Revisiting the definition of bronchopulmonary dysplasia in premature infants at a single center quaternary neonatal intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37612680" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparison of two novel diagnostic criteria for bronchopulmonary dysplasia in predicting adverse outcomes of preterm infants: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726936" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Controversy surrounding the use of home oxygen for premature infants with bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17306659" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Trends in neonatal morbidity and mortality for very low birthweight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10835057" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19336371" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20732945" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26348753" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20643728" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Epidemiological characteristics and resource use in neonates with bronchopulmonary dysplasia: 1993-2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33246013" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Trends in Bronchopulmonary Dysplasia Among Extremely Preterm Infants in Japan, 2003-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30612812" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Black Race Is Associated with a Lower Risk of Bronchopulmonary Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22343395" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Altitude, oxygen and the definition of bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24699220" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Oxygen dependency as equivalent to bronchopulmonary dysplasia at different altitudes in newborns⩽1500 g at birth from the SIBEN network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24639412" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Epidemiology of bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24345305" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37059387" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Prediction Models for Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36624282" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Bronchopulmonary dysplasia prediction models: a systematic review and meta-analysis with validation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17989387" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Chronic lung disease after premature birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6538770" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Human lung growth in late gestation and in the neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6538770" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Human lung growth in late gestation and in the neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19706590" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26908662" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Placental Complications and Bronchopulmonary Dysplasia: EPIPAGE-2 Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20955846" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25469645" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27639458" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pulmonary Effects of Maternal Smoking on the Fetus and Child: Effects on Lung Development, Respiratory Morbidities, and Life Long Lung Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28249118" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antenatal Determinants of Bronchopulmonary Dysplasia and Late Respiratory Disease in Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2745302" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Chest wall restriction limits high airway pressure-induced lung injury in young rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2228868" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Lung overexpansion increases pulmonary microvascular protein permeability in young lambs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9284276" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21471086" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7767415" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29039883" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Volume-targeted versus pressure-limited ventilation in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27470692" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29144252" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Can We Understand the Pathobiology of Bronchopulmonary Dysplasia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3540251" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Development of lung antioxidant enzyme system in late gestation: possible implications for the prematurely born infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12069735" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Antioxidant enzyme activities are decreased in preterm infants and in neonates born via caesarean section.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19217596" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A multicenter study on the clinical outcome of chorioamnionitis in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21697236" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24120077" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : That chorioamnionitis is a risk factor for bronchopulmonary dysplasia--the case against.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31693123" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Association of Chorioamnionitis With Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review, Meta-analysis, and Metaregression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9369827" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19403497" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10525015" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Role of ureaplasma urealyticum in lung disease of prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19190528" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24445836" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23439637" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29363502" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Prevention of bronchopulmonary dysplasia in extremely low gestational age neonates: current evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32170033" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28396025" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28258737" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18762515" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30287068" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Role of Genetic Susceptibility in the Development of Bronchopulmonary Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23897914" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A genome-wide association study (GWAS) for bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172140" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Genetic Contributions to the Development of Complications in Preterm Newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25449221" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Integrated genomic analyses in bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9670828" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23615175" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11099603" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Lung elastic tissue maturation and perturbations during the evolution of chronic lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8165067" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19336372" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21646264" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20335295" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496605" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Dysfunction of pulmonary surfactant in chronically ventilated premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17272782" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19336373" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25997993" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Angiogenic Factors in Cord Blood of Preterm Infants Predicts Subsequently Developing Bronchopulmonary Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20004912" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Maternal preeclampsia predicts the development of bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24039136" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Prenatal inflammatory risk factors for development of bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29622720" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Infant Pulmonary Function Testing and Phenotypes in Severe Bronchopulmonary Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/331223" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Chronic pulmonary disease in neonates after artificial ventilation: distribution of ventilation and pulmonary interstitial emphysema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16777823" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Summary proceedings from the bronchopulmonary dysplasia group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27908648" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26593081" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Hypoxic Episodes in Bronchopulmonary Dysplasia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
